Northland raised the firm’s price target on BioLife Solutions (BLFS) to $31 from $28 and keeps an Outperform rating on the shares. With the divestiture of its freezer businesses and the recent sale of SciSafe biostorage, the firm believes BioLife is positioned to “emerge as a leading consolidator in the sector” as the company refocuses on its core expertise in biopreservation media and cell processing products and services for cell and gene therapies, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLFS:
- BioLife Solutions Strengthens Board with Tony J. Hunt Appointment
- Azenta upgraded to Overweight, named new ‘Best Idea’ at Stephens
- BioLife Solutions appoints Hunt to board of directors
- BioLife Solutions price target raised to $33 from $30 at KeyBanc
- BioLife Solutions price target lowered to $27 from $29 at H.C. Wainwright